Linked Life Data

17086939

Source:http://linkedlifedata.com/resource/pubmed/id/17086939

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2006-11-7
pubmed:abstractText
Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1472-4472
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
936-45
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:17086939-Adjuvants, Immunologic, pubmed-meshheading:17086939-Animals, pubmed-meshheading:17086939-Clinical Trials, Phase I as Topic, pubmed-meshheading:17086939-Clinical Trials, Phase II as Topic, pubmed-meshheading:17086939-Clinical Trials, Phase III as Topic, pubmed-meshheading:17086939-Cognition Disorders, pubmed-meshheading:17086939-Diabetes Mellitus, Type 2, pubmed-meshheading:17086939-Growth Hormone-Releasing Hormone, pubmed-meshheading:17086939-HIV Wasting Syndrome, pubmed-meshheading:17086939-HIV-Associated Lipodystrophy Syndrome, pubmed-meshheading:17086939-Hip Fractures, pubmed-meshheading:17086939-Humans, pubmed-meshheading:17086939-Lipid Metabolism, pubmed-meshheading:17086939-Peptides, pubmed-meshheading:17086939-Recombinant Proteins, pubmed-meshheading:17086939-Sleep Disorders, pubmed-meshheading:17086939-Structure-Activity Relationship
pubmed:year
2006
pubmed:articleTitle
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.
pubmed:affiliation
The Chinese University of Hong Kong, Division of Clinical Pharmacology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. btomlinson@cuhk.edu.hk
pubmed:publicationType
Journal Article, Review